Wide Ranks

INBX

Inhibrx Biosciences, Inc.

15.63

Top Statistics
Market Cap 226 M Forward PE -1.42 Revenue Growth 233.30 %
Current Ratio 6.20 Trailing PE 0.1309 Earnings Growth 0.00 %
Profit Margins 101974.22 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 0.0570 Enterprise / Revenue -10.22 Price To Sales Trailing12 Months 134.12
Profitability
Profit Margins 101974.22 % Operating Margins -160898.00 %
Balance Sheet
Total Cash 226 M Total Cash Per Share 15.67 Total Debt 2 M
Total Debt To Equity 0.9900 Current Ratio 6.20 Book Value Per Share 15.15
All Measures
Short Ratio 1406.00 % Message Board Id finmb_1873020488 Shares Short Prior Month 742518
City La Jolla Uuid 65117bf8-50e3-3c16-a5dd-bee97e3c0678 Previous Close 15.45
First Trade Date Epoch Utc 1 B Book Value 15.15 Total Debt 2 M
Volume 30886 Price To Book 1.03 Fifty Two Week Low 10.80
Total Cash Per Share 15.67 Total Revenue 1 M Shares Short Previous Month Date 1 B
Max Age 86400 Sand P52 Week Change 0.3133 Operating Margins -160898.00 %
Net Income To Common 1 B Implied Shares Outstanding 14 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 93440 Average Volume10days 93440
Total Cash 226 M Next Fiscal Year End 1 B Revenue Per Share 0.1170
Held Percent Insiders 0.2355 Trailing PE 0.1309 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 15.45 Target Low Price 0.0000
Gmt Off Set Milliseconds -18000000 Fifty Day Average 15.50 Open 15.50
Dividend Yield 0.00 % State CA Time Zone Short Name EST
Trailing Eps 119.39 Day Low 15.48 Address1 11025 North Torrey Pines Road
Shares Outstanding 14 M Price Hint 2 Target High Price 0.0000
Website https://inhibrx.com 52 Week Change -0.0918 Average Volume 91189
Forward Eps -11.03 Recommendation Key none Quick Ratio 584.50 %
Is_sp_500 False Regular Market Day High 15.77 Profit Margins 101974.22 %
Debt To Equity 0.9900 Fifty Two Week High 18.95 Day High 15.77
Shares Short 895657 Regular Market Open 15.50 Industry Key biotechnology
Earnings Growth 0.00 % Enterprise To Revenue -10.22 Revenue Growth 233.30 %
Shares Percent Shares Out 0.0675 Operating Cashflow -167172000 Currency USD
Time Zone Full Name America/New_York Market Cap 226 M Is_nasdaq_100 False
Zip 92037 Quote Type EQUITY Industry Biotechnology
Long Name Inhibrx Biosciences, Inc. Regular Market Day Low 15.48 Held Percent Institutions 0.6749
Current Price 15.63 Address2 Suite 140 Enterprise To Ebitda 0.0570
Financial Currency USD Current Ratio 6.20 Industry Disp Biotechnology
Country United States Float Shares 7 M Two Hundred Day Average 14.74
Enterprise Value -17249296 Price To Sales Trailing12 Months 134.12 Forward PE -1.42
Regular Market Volume 30886 Ebitda -300927008 Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions.

Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma.

The company was incorporated in 2024 and is based in La Jolla, California.